TY - JOUR
T1 - Mycobacterium abscessus and β-lactams
T2 - Emerging insights and potential opportunities
AU - Story-Roller, Elizabeth
AU - Maggioncalda, Emily C.
AU - Cohen, Keira A.
AU - Lamichhane, Gyanu
N1 - Funding Information:
This work was supported by the Cystic Fibrosis Foundation grant LAMICH17GO and NIH grant R21 AI121805. ES-R was supported by the NIH T32 AI007291. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Cystic Fibrosis Foundation or the National Institutes of Health.
Publisher Copyright:
© 2007 - 2018 Frontiers Media S.A. All Rights Reserved.
PY - 2018/9/25
Y1 - 2018/9/25
N2 - β-lactams, the most widely used class of antibiotics, are well-tolerated, and their molecular mechanisms of action against many bacteria are well-documented. Mycobacterium abscessus (Mab) is a highly drug-resistant rapidly-growing nontuberculous mycobacteria (NTM). Only in recent years have we started to gain insight into the unique relationship between β-lactams and their targets in Mab. In this mini-review, we summarize recent findings that have begun to unravel the molecular basis for overall efficacy of β-lactams against Mab and discuss emerging evidence that indicates that we have yet to harness the full potential of this antibiotic class to treat Mab infections.
AB - β-lactams, the most widely used class of antibiotics, are well-tolerated, and their molecular mechanisms of action against many bacteria are well-documented. Mycobacterium abscessus (Mab) is a highly drug-resistant rapidly-growing nontuberculous mycobacteria (NTM). Only in recent years have we started to gain insight into the unique relationship between β-lactams and their targets in Mab. In this mini-review, we summarize recent findings that have begun to unravel the molecular basis for overall efficacy of β-lactams against Mab and discuss emerging evidence that indicates that we have yet to harness the full potential of this antibiotic class to treat Mab infections.
KW - LD-transpeptidase
KW - Mycobacterium abscessus
KW - Peptidoglycan
KW - β-lactamase inhibitor
KW - β-lactams
UR - http://www.scopus.com/inward/record.url?scp=85055126253&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85055126253&partnerID=8YFLogxK
U2 - 10.3389/fmicb.2018.02273
DO - 10.3389/fmicb.2018.02273
M3 - Review article
C2 - 30319581
AN - SCOPUS:85055126253
SN - 1664-302X
VL - 9
JO - Frontiers in Microbiology
JF - Frontiers in Microbiology
IS - SEP
M1 - 2273
ER -